This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krajden, M. Articles by Comanor, L. Search for Related Content PubMed PubMed Citation Articles by Krajden, M. Articles by Comanor, L.

Evaluation of the Core Antigen Assay as a Second-Line Supplemental Test for Diagnosis of Active Hepatitis C Virus Infection

British Columbia Center for Disease Control, Vancouver, British Columbia, Canada,¹ Bayer Healthcare LLC, Berkeley, California,² Independent Research Consultant, Palo Alto, California³

Received 24 February 2004/ Returned for modification 12 April 2004/ Accepted 9 May 2004

The British Columbia Center for Disease Control laboratory performs approximately 95% of all hepatitis C virus (HCV) antibody tests for the province's 4 million inhabitants. In 2002, the laboratory tested 96,000 specimens for anti-HCV antibodies, of which 4,800 (5%) were seroreactive and required confirmation of active infection. Although HCV RNA assays with a sensitivity of 50 IU/ml or less are recommended for the confirmation of active HCV infection, given the large number of seroreactive specimens tested annually, we evaluated the Ortho trak-C assay (OTCA) as a second-line confirmatory test and determined its limit of detection (LoD). Of 502 specimens from treatment-naïve anti-HCV-positive individuals, 478 had sufficient volumes for evaluation by the OTCA and HCV RNA tests. Core antigen was not detected in 147 of 478 (30.8%) of these specimens, of which 37 of 147 (25.2%) were shown to be viremic by the VERSANT HCV (version 3.0) (branched-DNA) assay and/or the VERSANT HCV qualitative assay. Testing of 144 replicates of a World Health Organization standard dilution series indicated that the LoD of OTCA was 27,000 IU/ml. This LoD is consistent with the inability of OTCA to detect core antigen in clinical specimens with low viral loads. We conclude that OTCA has limited value as a confirmatory test for the diagnosis of active HCV infection because 37 of 367 (10%) of viremic specimens had undetectable core antigen. Qualitative HCV RNA testing remains the present standard for the confirmation of active HCV infection in the diagnostic setting.

This article has been cited by other articles:

• Schnuriger, A., Dominguez, S., Valantin, M.-A., Tubiana, R., Duvivier, C., Ghosn, J., Simon, A., Katlama, C., Thibault, V. (2006). Early Detection of Hepatitis C Virus Infection by Use of a New Combined Antigen-Antibody Detection Assay: Potential Use for High-Risk Individuals. J. Clin. Microbiol. 44: 1561-1563 [Abstract] [Full Text]  
• Laperche, S., Le Marrec, N., Girault, A., Bouchardeau, F., Servant-Delmas, A., Maniez-Montreuil, M., Gallian, P., Levayer, T., Morel, P., Simon, N. (2005). Simultaneous Detection of Hepatitis C Virus (HCV) Core Antigen and Anti-HCV Antibodies Improves the Early Detection of HCV Infection. J. Clin. Microbiol. 43: 3877-3883 [Abstract] [Full Text]